FN2 Earnings Intelligence
Royalty Pharma plc income statement
Royalty Pharma plc (RPRX) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $1,541 | $1,710.8 | $477 | $929 | $618.7 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $2,289.5 | $2,237.2 | $2,354.6 | $2,263.6 | $2,378.2 |
| % Growth | 7.9% | -2.3% | 5.2% | -3.9% | 5.1% |
| Gross Profit | - | - | - | - | - |
| % Margin | - | - | - | - | - |
| EBITDA | - | - | - | - | $1,563.4 |
| % Margin | - | - | - | - | 65.7% |
| Net Income | $619.7 | $42.8 | $1,134.8 | $859 | $770.9 |
| % Margin | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| Diluted EPS | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| % Growth | 12.9% | -93.3% | 2,430.0% | -24.5% | -6.8% |
| Operating Cash Flow | $2,017.5 | $2,144 | $2,987.8 | $2,769 | $2,489.8 |
| CapEx | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $2,289.5 | $2,237.2 | $2,354.6 | $2,263.6 | $2,378.2 |
| Gross Profit | - | - | - | - | - |
| EBITDA | - | - | - | - | $1,563.4 |
| Net Income | $619.7 | $42.8 | $1,134.8 | $859 | $770.9 |
| Diluted EPS | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,541 | $1,710.8 | $477 | $929 | $618.7 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $7,096.1 | $6,118.8 | $6,135.3 | $6,614.7 | $8,570.9 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2,017.5 | $2,144 | $2,987.8 | $2,769 | $2,489.8 |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 7.9% | -2.3% | 5.2% | -3.9% | 5.1% |
| Gross Margin | - | - | - | - | - |
| EBITDA Margin | - | - | - | - | 65.7% |
| Net Margin | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| FCF Margin | - | - | - | - | - |
| Diluted EPS Growth | 12.9% | -93.3% | 2,430.0% | -24.5% | -6.8% |
Get the RPRX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.